
Six Idaho Towns Banned Kratom Sales. The State Never Passed a Law.
The Pocatello City Council took its vote on a Thursday night with no public comment period, because none was required. It was unanimous, it took effect immediately, and it made every sale of kratom inside the city limits unlawful — the leaf, the extracts, the concentrated 7-hydroxymitragynine tablets that gas stations stock next to the energy drinks, and anything synthetic that resembles them. Possession stayed legal. Only the counter disappeared.
Chubbuck, the smaller city next door, had done the same thing twenty-four hours earlier. By the end of the week Pocatello had joined Kellogg, Idaho Falls, Blackfoot, Shelley, Bonneville County and Bingham County on a list that did not exist two years ago, and Franklin County commissioners were sitting through testimony on an ordinance that would go further than any of them: a ban on sale and possession, which would make it the first local government in Idaho to criminalize holding the plant.
Idaho has no state kratom law. It is not a controlled substance there. There is no minimum age to buy it. Lawmakers weighed both a ban and a regulatory framework during the 2026 session and passed neither, which is how a decision about a commercially sold opioid-like product ended up in front of six city councils and two boards of commissioners in a single state, with a third county taking testimony.
An ordinance that arrived before the statute
What happened in southeastern Idaho is not really a kratom story. It is a story about what fills a vacuum, and about the difference between the two instruments now being aimed at this market. City councils are banning a category. The federal government is banning a concentration. Those are not the same policy, and the gap between them is where patients, parents and prescribers currently live.
The Chubbuck city attorney, Ryan Lewis, was unusually candid about the mechanics. Once neighboring cities acted, he said, his city could not afford to be left out: if Chubbuck were the only one without an ordinance, the handful of retailers selling the product would simply relocate there. That is a border argument, not a health argument, and it explains the speed better than any toxicology report. Sequim, Washington, is working through the same arithmetic; a council member there said plainly in November that a local ban "won't make a big difference if they go to Carlsborg," but that it "makes a big statement to kids."
The testimony in Idaho did include grief. Tia Rustici told Pocatello's Nov. 5 hearing that her 23-year-old daughter, Kielee, died of acute mitragynine intoxication. Denae Jones told Franklin County commissioners that her niece died after using kratom powder, and she pushed back on the idea of exempting natural leaf from a ban, because natural leaf is what her niece took. A speaker at the Pocatello hearing cited state figures of 124 kratom-related deaths in Idaho since 2020, nine of them in Bannock County.
The other side of the room was not empty either. A construction worker named Tyson Merrill said kratom is what lets him function through pain from old fractures and surgeries. A scoliosis patient who has manufactured leaf products for a decade said it replaced prescription opioids for him. One retailer representative asked commissioners to limit the ordinance to synthetics, drop possession penalties for adults, and let the Legislature set a statewide rule in January.
Councilwoman Ann Swanson's summary before the Pocatello vote is probably the most honest sentence in the whole record: "I understand that people do benefit from this product or claim to. However, I do think that the dangers really outweigh the benefits for our city."
Washington aimed at a molecule, not a plant
Six weeks before Pocatello voted, the Department of Justice announced the federal version of this policy, and it looks nothing like a city ordinance.
On Oct. 9, the DEA issued two new notices of intent built on a revised HHS analysis. The operative numbers: 7-hydroxymitragynine and mitragynine pseudoindoxyl fall into Schedule I when either compound — or both combined — exceeds 1 milligram per gram in a solid product, or 1 milligram per milliliter in a liquid, or when the ratio of mitragynine to those compounds drops below 100 to 1. Three related substances, mitragynine pseudoindoxyl, MGM-15 and MGM-16, were already placed in Schedule I on Aug. 26 and stay there.
The threshold is the entire policy. Naturally occurring 7-OH is a minor alkaloid in kratom leaf, well under those limits, so botanical kratom stays outside federal control. What gets scheduled is the engineered product — the tablet that has been spiked or synthesized to deliver a mu-opioid hit closer to morphine than to a leaf, and that is sold under the same word, "kratom," on the same shelf.
What the threshold means at a retail counter
Put the two rules side by side and the incoherence is visible. A shop in Pocatello cannot legally sell a bag of plain leaf powder, which the federal government has declined to control and which the FDA has not approved but has also not scheduled. A shop twelve miles south, in a county that has not acted, can sell the same bag — and can also sell the concentrated tablet until the DEA's order is signed, then cannot.
The FDA has been explicit that this is an unapproved drug problem rather than a supplement problem. It has issued warning letters to firms marketing 7-OH products, seized shipments, and published its own toxicological assessment calling concentrated 7-OH an emerging opioid threat. The agency has approved no use for kratom in any form. NIDA, for its part, notes that fatal overdose from kratom alone appears to be extremely rare — which is true, and which is also why the two sides of this argument can both be telling the truth.
As of this week, DEA has still not issued a temporary scheduling order for 7-OH itself. The notices of intent run their comment periods; the order is pending. So the most potent products in the category remain unscheduled at the federal level while a mid-sized Idaho city has banned the entire category outright.
The number both sides quote
Everyone in this fight cites the same CDC analysis, published in MMWR in March, and it does not settle the question they are using it for.
The National Poison Data System logged 14,449 kratom-related exposure reports between 2015 and 2025. Of those, 3,434 came in 2025 alone — roughly a 1,200 percent increase over the 258 reports in 2015. The authors counted 233 deaths associated with kratom exposure reports across the decade; in 79 percent of them more than one substance was involved, opioids appeared in 62 percent, and polysubstance cases were more likely to end in hospitalization.
America's Poison Centers logged 3,190 reports involving kratom or its derivatives through June of this year. If that pace holds, 2026 finishes nearly 68 percent above 2025.
Here is what the dataset cannot tell you, and what both the ban side and the industry side quietly skip: the reports do not distinguish traditional leaf from the new concentrated and semisynthetic products. Nobody can say from this data how much of the ten-year rise is a molecule getting stronger and how much is a market getting bigger. Local numbers have their own fog. Clallam County, Washington, has recorded seven deaths in seven years with kratom as a contributing factor; the state had 15 deaths with kratom in the system so far this year against a peak of 38 in 2023, which is not the shape of an exponential curve.
A sales ban is not a treatment plan
The clinical question that got the least airtime in Idaho is the one a family is most likely to face at 2 a.m.: what do you do for someone who has been taking these products daily and stops?
The American College of Medical Toxicology answered part of it in August. Its position statement says 7-OH produces opioid-like effects including dependence and withdrawal, that concentrated products have been linked to overdose and death, and that cases of 7-OH withdrawal and dependence have been treated successfully with buprenorphine or methadone — the same medications used for any opioid use disorder. Naloxone reverses 7-OH respiratory depression in animal studies and human case reports, and about one in four people reported to poison centers after exposure to kratom or 7-OH alone were hospitalized.
The college's practical instruction to clinicians is blunt: ask specifically about kratom, about 7-OH products, about the brands sold at gas stations. Not "any substance use" — those words. Patients often do not consider what they are buying to be a drug, and a treatment plan built on a screening question that never gets asked is a plan built on nothing.
What that means on the ground is that a city ordinance removes supply without adding a single prescriber. Someone in Pocatello who was managing pain or staving off withdrawal with a $12 bottle now has three options: drive to Utah, order online, or stop. If they stop and the withdrawal is severe enough, the evidence-based answer is a buprenorphine induction and ongoing care, which is exactly what medication-assisted treatment is for, and which requires a clinic that will see them this week. Idaho did not create one on Thursday.
Rhode Island went the other direction
The comparison that makes the Idaho approach look like a choice rather than an inevitability is Rhode Island. This year it became the first state to replace a statewide kratom ban with a regulated market for adults 21 and over, while still prohibiting synthetic kratom alkaloids. Coeur d'Alene, in Idaho's panhandle, took a smaller version of the same path in September: a city license requirement and a 21-and-over sales rule instead of a ban.
At the state level the map is genuinely fragmented rather than trending one way. The National Conference of State Legislatures counts at least 31 states regulating kratom in some form; the Rockefeller Institute of Government counts 36 states that introduced kratom, 7-OH or synthetic-kratom legislation across the 2025 and 2026 sessions, with 14 banning or scheduling the plant, 13 setting potency limits and 24 imposing sales restrictions, categories that overlap freely. Tennessee's statewide ban took effect in July. Massachusetts placed all forms of kratom in Schedule I under state law for a year by executive order in August. Pennsylvania's House is moving a bill that would do the opposite of Idaho: license retailers, allow natural leaf sales to adults 21 and up, and prohibit products above 0.5 percent 7-OH.
Two futures, both defensible on the same poison-center curve, and the difference is whether the state intends to test products or remove them.
What to watch, and what to do
Franklin County commissioners said they will review 42 written comments and decide in the first week of December; if they pass the possession ban, the first arrest for holding a legal-in-Utah leaf will be a test case nobody planned. The Idaho Legislature convenes in January with the same bills it declined to pass this year. The DEA's 7-OH order is still pending, and when it lands it will apply to a set of products that several Idaho cities have already outlawed in every form.
For families, the practical items are less ambiguous than the politics. Anyone using concentrated 7-OH products daily should assume physical dependence and should not stop abruptly without a plan; naloxone still works on these overdoses and is worth trying even in a mixed ingestion with alcohol. And anyone looking for help stopping should say the words "kratom" and "7-OH" out loud to a clinician, because the treatment that works — buprenorphine, titrated and continued — is the ordinary standard of care for opioid addiction treatment, whether or not the substance that caused it was ever scheduled by anyone.
Sources
- Idaho Capital Sun, "Pocatello bans kratom sales; Franklin County weighs Idaho's first possession ban," Nov. 20, 2026
- U.S. Department of Justice, "Department of Justice Announces Updates to Emergency Scheduling Actions for 7-OH and Related Opioid Substances," Oct. 9, 2026
- U.S. Food and Drug Administration, "Hiding in Plain Sight: 7-OH Products"
- Towers EB, Thomas YT, Holstege CP, Farah R. Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, 2015–2025. MMWR 2026;75:139–145
- American College of Medical Toxicology, position statement on 7-hydroxymitragynine and other kratom compounds, approved August 2026
- Stateline, "Kratom, 7-OH laws diverge amid the spread of potent synthetic products," Oct. 5, 2026
- Sequim Gazette, "City Council considers kratom regulation," Nov. 18, 2026
Editorial Board
LADC, LCPC, CASAC
The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.
Related Articles

Florida Credits a $22.5 Million Grant Program for a 60 Percent Drop in Fentanyl Deaths. The Autopsy Data Can't Say That.
Fentanyl deaths in Florida fell nearly 60 percent in two years. The governor credits a grant program; the death data cannot separate it from everything else.

DEA Seizes 50 Million Deadly Doses of Fentanyl During Inaugural Fentanyl Free America Summit
DEA's inaugural Fentanyl Free America Summit concludes with enforcement results showing over 4 million pills and 1,158 kilograms of fentanyl powder seized in six weeks.

Massachusetts Opioid Overdose Deaths Drop to Historic Lows — Expert Explains What's Working
For the first time since 2013, Massachusetts recorded fewer than 1,000 opioid-related overdose deaths in 2025, marking a nearly 60% decline from the 2022 peak.